Introduction: Metered cryospray (MCS) is a bronchoscopic treatment that uses liquid nitrogen to ablate, and repopulate the bronchial epithelium with a healthier phenotype, in patients with COPD with chronic bronchitis (CB).
Aims and objectives: To investigate the effect of MCS on symptoms of CB in patients with COPD with CB.
Methods: St. George?s respiratory questionnaire (SGRQ) and COPD assessment test (CAT) were collected from 17 subjects, in patients receiving open-label crossover MCS treatment. NCT03892694.
Results: Change in SGRQ total (-8.5 points n=15 p=0.04) and CAT (-3.5 points n=15 p=0.02) scores, were observed at 6-months post-MCS, relative to baseline. Change at 6-months post-MCS relative to baseline, was observed in SGRQ total (-12.1 points n=15 p=0.02) and CAT (-3.3 points n=15 p=0.03) scores, compared to change at 6-months post-sham procedure relative to baseline.
| Baseline (17) | 6-months (15) | Difference over time | p valve | |
| SGRQ Total | 58.3 ± 10.5 | 49.7 ± 16.8 | -8.5 ± 14.3 | 0.04 |
| SGRQ Symptom | 65.2 ± 17.3 | 58.8 ± 21.9 | -6.5 ± 21.0 | 0.25 |
| SGRQ Activities | 76.4 ± 15.0 | 67.4 ± 20.1 | -9.4 ± 17.3 | 0.05 |
| SGRQ Impact | 46.0 ± 9.4 | 36.9 ± 17.5 | -8.6 ± 13.3 | 0.03 |
| CAT | 22.2 ± 4.4 | 18.7 ± 6.6 | -3.5 ± 5.1 | 0.02 |
| CAT cough + phlegm score | 5.2 ± 1.9 | 3.8 ± 1.8 | -1.5 ± 2.1 | 0.02 |
Changes in SGRQ and CAT scores at 6-months post-MCS, relative to baseline. p-value calculated with paired t-test; n=15
Conclusions: The clinically meaningful and statistically significant changes in measures of symptoms of CB, in patients receiving cross-over MCS, reiterates that MCS is efficacious in improving quality of life in patients with COPD with CB.